CohBar Co-Founder and Scientific Advisor Dr. David Sinclair Named as one of TIME Magazine’s Health Care 50
Cited for his groundbreaking work on the underlying metabolic causes of aging
MENLO PARK, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that co-founder and scientific advisor Dr. David Sinclair is featured among TIME Magazine’s Health Care 50, a profile of fifty people changing healthcare in 2018. The profile cites Dr. Sinclair’s ongoing work in addressing and even reversing typical signs of aging, including high blood pressure, weight gain and decreased metabolism. Dr. Sinclair was also featured as one of TIME Magazine’s 100 Most Influential People in 2014.
“This recognition of Dr. Sinclair by TIME Magazine underscores his pioneering work in the field of aging, particularly in the arena of mitochondrial genetics and the biology of aging,” said Simon Allen, Chief Executive Officer of CohBar. “We remain grateful to Dr. Sinclair for his ongoing guidance and contributions to the significant advances being made by CohBar in the development of mitochondrial-derived peptides to treat age-related diseases and extend healthy lifespan.”
Dr. Sinclair is a Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School. He is best known for his work on understanding why we age and how to slow its effects. He obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney in 1995. He worked as a postdoctoral researcher at M.I.T. with Dr. Leonard Guarente where he co-discovered a cause of aging for yeast as well as the role of Sir2 in epigenetic changes driven by genome instability. In 1999, he was recruited to Harvard Medical School where his laboratory's research has focused primarily on understanding the role of sirtuins in disease and aging, with associated interests in chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, and cancer. He has also contributed to the understanding of how sirtuins are modulated by endogenous molecules and pharmacological agents such as resveratrol. In addition to CohBar, Dr. Sinclair is co-founder of several biotechnology companies (Sirtris, Ovascience, Genocea, MetroBiotech, ArcBio, Liberty Biosecurity, Life Biosciences, Spotlight, Jumpstart, and Iduna) and is on the boards of several others. He is also co-founder and co-chief editor of the journal Aging. His work is featured in five books, two documentary movies, 60 Minutes, Morgan Freeman's “Through the Wormhole” and other media. He has published more than 150 scientific articles, is an inventor on 35 patents, and has received 34 awards and honors including the CSL Prize, The Australian Commonwealth Prize, Thompson Prize, Helen Hay Whitney Postdoctoral Award, Charles Hood Fellowship, Leukemia Society Fellowship, Ludwig Scholarship, Harvard-Armenise Fellowship, American Association for Aging Research Fellowship, Nathan Shock Award from the National Institutes of Health, an Excellence in Teaching Award from Harvard Medical School, Ellison Medical Foundation Junior and Senior Scholar Awards, Merck Prize, Genzyme Outstanding Achievement in Biomedical Science Award, Bio-Innovator Award, David Murdock-Dole Lectureship, Fisher Honorary Lectureship, Les Lazarus Lectureship, Australian Medical Research Medal, The Frontiers in Aging and Regeneration Award, Top 100 Australian Innovators, Pioneer Award from the National Institutes of Health, the Irving Wright Award, Advance Global Australian Award, a NASA iTECH award, and TIME magazine’s list of the “100 most influential people in the world.” In 2018 he became an Officer of the Order of Australia.
The TIME Magazine profile can be found here.
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs. For additional company information, please visit www.cohbar.com.
This news release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the therapeutic potential of mitochondrial-derived peptides for the treatment of age-related diseases. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, such as the possibility of unfavorable study results, including unfavorable new data and additional analyses of existing data; risks associated with initial data, including the risk that results of additional pre-clinical or clinical studies may be different from (including less favorable than) the earlier data results and may not support further clinical development of CohBar’s therapeutic candidates. Additional risks and uncertainties include CohBar’s ability to retain key personnel, expand its research operations, and obtain financing necessary to continue its operations and fund its candidate programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.
Jon Stern, COO
LifeSci Advisors, LLC
Released November 8, 2018